{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:46:52Z","timestamp":1784116012010,"version":"3.55.0"},"reference-count":38,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:p>ABSTRACT  Background Occult hepatitis B infection is characterized by negative hepatitis B surface antigen (HBsAg) and also detectable hepatitis B virus (HBV) -DNA, with or without hepatitis B core antibody (anti-HBc). HBV reactivation in individuals under immunosuppressive therapy is critical, occurring in occult HBV.  Objective In this study, we aimed to determine the prevalence of occult HBV infection among hepatitis B surface antigen negative in cancer patients before receiving chemotherapy.  Methods Sera from 204 cancer patients who were negative for HBsAg, were tested for anti-HBc antibodies. The samples that were negative for HBsAg but positive for anti-HBc also examined for HBV-DNA by polymerase chain reaction (PCR).  Results Of the 204 HBsAg negative blood samples, 11 (5.4%) samples were positive for anti-HBc antibodies. HBV-DNA was detected in 9\/11 (81%) of anti-HBc positive samples. Occult HBV infection in hematological cancers was more than solid cancers, 4.8% and 4.3% respectively. There was no significant difference in HBc antibody positivity based on vaccination, previous blood transfusions, history of familial hepatitis or biochemical parameters (ALT, AST, total and direct bilirubin levels) (P&gt;0.05).  Conclusion Screening of occult HBV infection by HBsAg, HBV DNA and anti HB core antibody should be suggested as a routine investigation in cancer patients before receiving chemotherapy.<\/jats:p>","DOI":"10.1590\/s0004-28032016000300010","type":"journal-article","created":{"date-parts":[[2016,7,16]],"date-time":"2016-07-16T13:30:57Z","timestamp":1468675857000},"page":"175-179","source":"Crossref","is-referenced-by-count":8,"title":["PREVALENCE OF OCCULT HEPATITIS B INFECTION IN IRANIAN CANCER PATIENTS BEFORE CHEMOTHERAPY TREATMENT"],"prefix":"10.1590","volume":"53","author":[{"given":"Mahmud","family":"BAGHBANIAN","sequence":"first","affiliation":[{"name":"Shahid Sadoughi University of Medical Sciences and Health Services,  Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"HALVANI","sequence":"additional","affiliation":[{"name":"Shahid Sadoughi University of Medical Sciences and Health Services,  Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan Salman","family":"ROGHANI","sequence":"additional","affiliation":[{"name":"Shahid Sadoughi University of Medical Sciences and Health Services,  Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hassan","family":"LOTFI","sequence":"additional","affiliation":[{"name":"Shaheed Sadoughi University of Medical Sciences,  Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Frahat","family":"YAZDI","sequence":"additional","affiliation":[{"name":"Shahid Sadoughi University of Medical Sciences and Health Services,  Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan-Ali","family":"VAHEDIAN-ARDAKANI","sequence":"additional","affiliation":[{"name":"Shahid Sadoughi University of Medical Sciences and Health Services,  Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190701411441","article-title":"Rituximab-related viral infections in lymphoma patients","volume":"48","author":"Aksoy S","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/sj.bjc.6690652","article-title":"Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours","volume":"81","author":"Alexopoulos CG","year":"1999","journal-title":"British J Cancer"},{"key":"ref3","first-page":"14","article-title":"Occult hepatitis B virus infection","volume":"3","author":"Allain JP","year":"2009","journal-title":"Hepatitis B Annual"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mpo.10230","article-title":"Transfusion associated hepatitis in children with hematological malignancy in Northern India","volume":"41","author":"Arora B","year":"2003","journal-title":"Med Pediatr Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer the results of 20 years of follow-up","volume":"332","author":"Bonadonna G","year":"1995","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jhep.2009.05.020","article-title":"Transfusion-transmitted hepatitis B virus infection","volume":"51","author":"Candotti D","year":"2009","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1440-1746.2009.06006.x","article-title":"Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection","volume":"25","author":"Chen LW","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"ref8","first-page":"376","article-title":"Prospective evaluation of seropositive occult hepatitis B viral infection in lymphoma patients receiving chemotherapy","volume":"17","author":"Cheung WI","year":"2011","journal-title":"Hong Kong Med J"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.ejca.2010.03.034","article-title":"Hepatitis B virus-related hepatocarcinogenesis molecular oncogenic potential of clear or occult infections","volume":"46","author":"DeMitri MS","year":"2010","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1386-6532(03)00117-3","article-title":"Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C","volume":"29","author":"Fabris P","year":"2004","journal-title":"J Clin Virol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JOP.2010.000133","article-title":"Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors A nationwide survey of medical oncologists","volume":"7","author":"Fiona LD","year":"2011","journal-title":"JOP"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.1840180605","article-title":"Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B","volume":"18","author":"Fong TL","year":"1993","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s15010-009-9019-1","article-title":"Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy","volume":"38","author":"Francisci D","year":"2010","journal-title":"Infection"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jmv.20963","article-title":"HBsAg non-reactive HBV infection in blood donors transmission and pathogenicity","volume":"79","author":"Gerlich WH","year":"2007","journal-title":"J Med Virol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2006.04.015","article-title":"Kinetics and risk of de novo hepatitis Infection in HBsAg negative patients undergoing chemotherapy","volume":"131","author":"Hui CK","year":"2006","journal-title":"Gastroenterology"},{"key":"ref16","first-page":"4068","article-title":"Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C","volume":"40","author":"Kao JH","year":"2002","journal-title":"J ClinMicrobiol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.1990.8.6.963","article-title":"Prognostic significance of actual dose intensity in diffuse large-cell lymphoma results of a tree-structured survival analysis","volume":"8","author":"Kwak LW","year":"1990","journal-title":"J ClinOncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2141.2006.06465.x","article-title":"Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies","volume":"136","author":"Lalazar G","year":"2007","journal-title":"Br J Haematol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/jhep.2002.35068","article-title":"Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation","volume":"36","author":"Lau GK","year":"2002","journal-title":"Hepatology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood.V99.7.2324","article-title":"High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation","volume":"99","author":"Lau GK","year":"2002","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, arid current and emerging prevention and control measures","volume":"11","author":"Lavanchy D","year":"2004","journal-title":"Journal of Viral Hepatitis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00277-003-0825-8","article-title":"Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy","volume":"83","author":"Leaw SJ","year":"2004","journal-title":"Ann Hematol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B update","volume":"50","author":"Lok AS","year":"2009","journal-title":"Hepatology"},{"key":"ref24","first-page":"166","article-title":"Seroprevalence of hepatitis B and C viral infections at diagnosis and during the course of treatment in childhood malignancies","volume":"37","author":"Marwaha R","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.dld.2006.12.017","article-title":"Prophylaxis and treatment of hepatitis B in immune compromised patients","volume":"39","author":"Marzano A","year":"2007","journal-title":"Digestive and Liver Disease"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/jmv.20943","article-title":"Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C","volume":"79","author":"Mrani S","year":"2007","journal-title":"J Med Virol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/01.TP.0000151661.52601.FB","article-title":"Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection","volume":"79","author":"Onozawa M","year":"2005","journal-title":"Transplantation"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-009-0806-7","article-title":"Reactivation of hepatitis B virus following rituximab-based regimens a serious complication in both HBsAg-positive and HBsAg-negative patients","volume":"89","author":"Pei SN","year":"2010","journal-title":"Annals of Hematology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jhep.2006.10.007","article-title":"Occult hepatitis B virus infection","volume":"46","author":"Raimondo G","year":"2007","journal-title":"J Hepatol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2008.07.014","article-title":"Statements from the Taormina expert meeting on occult hepatitis B virus infection J","volume":"49","author":"Raimondo G","year":"2008","journal-title":"Hepatol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2008.01.023","article-title":"Occult hepatitis B virus in liver tissue of individuals without hepatic disease","volume":"48","author":"Raimondo G","year":"2008","journal-title":"J Hepatol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/bmj.320.7232.403","article-title":"Prospective investigation of transfusion transmitted infection in recipients of over 20000 units of blood TTI Study Group","volume":"320","author":"Regan FA","year":"2000","journal-title":"BMJ"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1590\/S1413-86702004000600007","article-title":"The influence of occult infection with hepatitis B virus on liver histology and response to interferon treatment in chronic hepatitis C patients","volume":"8","author":"Silva C","year":"2004","journal-title":"Braz J Infect Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s12664-013-0323-4","article-title":"Occult hepatitis B virus infection as a cause of post transfusion hepatitis in patients with cancers","volume":"32","author":"Sodhi JS","year":"2013","journal-title":"Indian J Gastroenterol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1473-3099(02)00345-6","article-title":"Occult hepatitis B","volume":"2","author":"Torbenson M","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors","volume":"62","author":"Yeo W","year":"2000","journal-title":"Journal Medical Virol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jmv.10430","article-title":"Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy a prospective study","volume":"70","author":"Yeo W","year":"2003","journal-title":"J Med Virol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.21051","article-title":"Diagnosis prevention and management of hepatitis B virus reactivation during anticancer therapy","volume":"43","author":"Yeo W","year":"2006","journal-title":"Hepatology"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v53n3\/1678-4219-ag-53-03-00175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T00:48:36Z","timestamp":1495586916000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032016000300175&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0004-28032016000300175"],"URL":"https:\/\/doi.org\/10.1590\/s0004-28032016000300010","relation":{},"ISSN":["0004-2803"],"issn-type":[{"value":"0004-2803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}